Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796666 · ClinicalTrials.gov registry record · Phase 3
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 131
- Enrollment target
NCT00796666 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 131 participants.
The verdict
NCT00796666, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 131 participants
- Enrollment target
Study Summary
As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled safety/efficacy database of the combination is limited.
Interventions
- DRUG Sitaxsentan
- DRUG Sitaxsentan and Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796666
The ClinicalTrials.gov registry entry for NCT00796666 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sitaxsentan is the first listed.
NCT00796666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796666 about?
NCT00796666 is a clinical study titled "Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil". As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled safety/efficacy database of the combination is limited.
What is the current status of trial NCT00796666?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 131 participants. The study started on 2009-05. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00796666?
The interventions under investigation include: Sitaxsentan (DRUG), Sitaxsentan and Sildenafil (DRUG).
Who is sponsoring clinical trial NCT00796666?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.